Is Buying Taro Pharmaceutical Industries LTD. Ordinary Share (NYSE:TARO), Having Lower Short Interest a Winning Strategy?

September 30, 2018 - By Billy Entrekin

The stock of Taro Pharmaceutical Industries LTD. Ordinary Share (NYSE:TARO) registered a decrease of 4.75% in short interest. TARO’s total short interest was 563,900 shares in September as published by FINRA. Its down 4.75% from 592,000 shares, reported previously. With 35,100 shares average volume, it will take short sellers 16 days to cover their TARO’s short positions. The short interest to Taro Pharmaceutical Industries LTD. Ordinary Share’s float is 5.7%.

The stock increased 0.27% or $0.26 during the last trading session, reaching $98.3. About 41,344 shares traded or 10.72% up from the average. Taro Pharmaceutical Industries Ltd. (NYSE:TARO) has declined 2.92% since September 30, 2017 and is downtrending. It has underperformed by 18.54% the S&P500.

Taro Pharmaceutical Industries Ltd., a science pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. The company has market cap of $3.88 billion. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. It has a 17.5 P/E ratio. The firm sells and distributes its products principally to drug industry wholesalers, drug store chains, mass merchandisers, healthcare institutions, and private pharmacies.

More news for Taro Pharmaceutical Industries Ltd. (NYSE:TARO) were recently published by:, which released: “Best ETFs for 2018: Don’t Sweat This Quarter for the SBIO ETF” on September 28, 2018.‘s article titled: “Taro Pharma nixes license agreement with NovaBiotics” and published on September 29, 2018 is yet another important article.

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: